Biolevate, a Paris-based company developing AI software for regulated life sciences operations, has raised €30 million in a Series A funding round co-led by RAISE France and Orange Ventures.
MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures also participated in the round.
Biolevate plans to use the funding to accelerate its international expansion, strengthen its product capabilities and scale deployments with life sciences organisations. The company is also expanding its presence in the United States with a new office in Boston.
Led by co-founder and CEO Joël Belafa, Biolevate develops an enterprise AI platform designed to turn scientific, regulatory and organisational knowledge into traceable workflows. Its software combines scientific evidence, regulatory knowledge, company context and AI agents to support work across research, clinical trials, health technology assessments, regulatory dossiers, drug discovery and drug development while maintaining human oversight and auditability.
